Mark provides strategic and transactional advice and functions as an outside general counsel to business enterprises, investors and entrepreneurs who are focused on innovation, technology development, and commercialization.
Mark’s practice involves all aspects of corporate and securities laws for emerging stage and start-up companies. He routinely advises clients on their growth and development and participates in a diverse array of transactions, from public offerings and private placements of securities to mergers and acquisitions. He also counsels clients on their daily corporate needs and has extensive experience assisting with federal and state securities law compliance.
Mark’s corporate finance practice experience includes the completion of numerous venture capital and private equity financings, representing both the funds providing the capital and the companies seeking funding.
Mark represents Merck Global Health Innovation Fund, which is Merck & Co. Inc.’s award winning corporate venture fund, on venture investments and acquisitions including the strategic combination transaction that resulted in the combination of eCardio Diagnostics, LLC and Preventice Inc. into a new holding company, Preventice Solutions, Inc. Following the Preventice strategic combination transaction, Mark continues to work closely with Preventice on a number of strategic initiatives, as well as general corporate matters. Mark also serves as outside general counsel to public companies in the life science space.